New antibody drug tested against severe COVID-19 in hospital patients
NCT ID NCT04644185
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This study tested an experimental antibody drug called SCTA01 in adults hospitalized with severe COVID-19. Participants received either the drug or a placebo to see if it helped them recover faster. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SCT study site
Somers Point, New Jersey, 08244, United States
-
SCT study site
Buenos Aires, Argentina
-
SCT study site
Uberlândia, Brazil
-
SCT study site
Talca, Chile
-
SCT study site
Rionegro, Colombia
-
SCT study site
Monterrey, Mexico
-
SCT study site
Lima, Peru
Conditions
Explore the condition pages connected to this study.